Medtronic Plc (NYSE:MDT) shares traded 1.44% higher at $82.41 on Wall Street last session.
MDT stock price is now -3.04% away from the 50-day moving average and -5.48% away from the 200-day moving average. The market capitalization of the company currently stands at $105.69B.
With the price target enhanced from $92 to $107, Citigroup Upgraded its rating from Neutral to Buy for Medtronic Plc (NYSE: MDT). On October 10, 2024, RBC Capital Mkts Upgraded its previous ‘Sector Perform’ rating to ‘Outperform’ on the stock increasing its target price from $98 to quote $105, while ‘Oppenheimer’ rates the stock as ‘Perform’
In other news, Wall Brett A., EVP & Pres Neuroscience sold 12,437 shares of the company’s stock on Jan 24 ’25. The stock was sold for $1,119,330 at an average price of $90.00. Upon completion of the transaction, the EVP & Pres Neuroscience now directly owns 40,979 shares in the company, valued at $3.38 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 24 ’25, Officer Wall Brett A. bought 12,437 shares of the business’s stock. A total of $1,119,330 was incurred on buying the stock at an average price of $90.00. A total of 0.17% of the company’s stock is owned by insiders.
During the past 12 months, Medtronic Plc has had a low of $75.96 and a high of $96.25. As of last week, the company has a debt-to-equity ratio of 0.59, a current ratio of 1.85, and a quick ratio of 1.42.
The net profit margin was 13.90% and return on equity was 9.49% for MDT. The company reported revenue of $8.29 billion for the quarter, compared to $8.09 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.51 percent.
